On July 16, 2010, Amneal Pharmaceuticals received FDA approval for new drug application 090606, a strategic move that positions the firm to expand its generic portfolio and capture broader market share in the targeted therapeutic category. This regulatory clearance allows Amneal to immediately bolster its manufacturing output and drive revenue growth following the patent expiration of the reference-listed drug.